What is a common expected result for a client receiving chemotherapy?

For clients receiving chemotherapy, a common expected result is a decreased platelet count. Chemotherapy targets rapidly dividing cells, which includes not only cancer cells but also healthy cells in the bone marrow responsible for producing blood components such as platelets. As a result, many patients experience thrombocytopenia, or a lower-than-normal platelet count, which can lead to increased risks of bleeding and bruising.

The other options do not align with typical chemotherapy effects on blood counts. Elevated white blood cell counts are not usually a result of chemotherapy; instead, chemotherapy commonly leads to leukopenia, which is a decrease in white blood cell count. An increased reticulocyte count, indicating increased red blood cell production, is also not a common effect of chemotherapy, as it frequently suppresses erythropoiesis, leading to anemia. Lastly, a normal red blood cell count is unlikely during chemotherapy treatment, as many patients experience a decrease in red blood cells (anemia) due to the impact on bone marrow function. Therefore, the decrease in platelet count is the most accurate expectation for clients undergoing chemotherapy.